Denis M Daigle

ORCID

Publication Activity (10 Years)

Years Active: 2020-2022
Publications (10 Years): 7

Top Venues

Antimicrobial agents and chemotherapy

Microbiology spectrum

Venatorx Pharmaceuticals Inc.

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Venatorx Pharmaceuticals Inc. Oct 1o 2010

United States

Director :: Biology

Publications

James A Karlowsky, Meredith A Hackel, Mark G Wise, David A Six, Tsuyoshi Uehara, Denis M Daigle, Susan M Cusick, Daniel C Pevear, Greg Moeck, Daniel F Sahm
In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program. Antimicrobial agents and chemotherapy 67 (1) (2022)
James A Karlowsky, Meredith A Hackel, Mark G Wise, David A Six, Tsuyoshi Uehara, Denis M Daigle, Susan M Cusick, Daniel C Pevear, Greg Moeck, Daniel F Sahm
In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program. Antimicrobial agents and chemotherapy 67 (1) (2022)
James A Karlowsky, Meredith A Hackel, Mark G Wise, David A Six, Tsuyoshi Uehara, Denis M Daigle, Susan M Cusick, Daniel C Pevear, Greg Moeck, Daniel F Sahm
In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program. Antimicrobial agents and chemotherapy 67 (1) (2022)
James A Karlowsky, Meredith A Hackel, Mark G Wise, David A Six, Tsuyoshi Uehara, Denis M Daigle, Susan M Cusick, Daniel C Pevear, Greg Moeck, Daniel F Sahm
In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program. Antimicrobial agents and chemotherapy 67 (1) (2022)
James A Karlowsky, Meredith A Hackel, Mark G Wise, David A Six, Tsuyoshi Uehara, Denis M Daigle, Susan M Cusick, Daniel C Pevear, Greg Moeck, Daniel F Sahm
In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program. Antimicrobial agents and chemotherapy (2022)
Elyse J Roach, Tsuyoshi Uehara, Denis M Daigle, David A Six, Cezar M Khursigara
The Next-Generation β-Lactamase Inhibitor Taniborbactam Restores the Morphological Effects of Cefepime in KPC-Producing Escherichia coli. Microbiology spectrum 9 (2) (2021)
Jodie C Hamrick, Jean Denis Docquier, Tsuyoshi Uehara, Cullen L Myers, David A Six, Cassandra L Chatwin, Kaitlyn J John, Salvador F Vernacchio, Susan M Cusick, Robert E L Trout, Cecilia Pozzi, Filomena De Luca, Manuela Benvenuti, Stefano Mangani, Bin Liu, Randy W Jackson, Greg Moeck, Luigi Xerri, Christopher J Burns, Daniel C Pevear, Denis M Daigle
VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy 64 (3) (2020)

Denis M Daigle.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Denis M Daigle